# Clinical Trials Data KRAS - Document 41

# Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01394120

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologic diagnosis of pancreas adenocarcinoma\n\* Clinical stage IV\n\* Feasible patient for chemotherapy\n\* Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic targets\n\* Informed written consent\n\nExclusion Criteria:\n\n\* Previous systemic treatment for advanced pancreas adenocarcinoma\n\* Contraindication to the administration of any of the drugs used in the study: capecitabine, 5Fluouracil, irinotecan, oxaliplatin, gemcitabine or erlotinib",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't explicitly exclude patients with a KRAS mutation. While KRAS mutations are common in pancreatic cancer, this trial description focuses on eligibility based on prior treatment, overall health, and tumor sample availability. Therefore, a patient with a KRAS mutation \*could\* be eligible provided they meet all other inclusion criteria and none of the exclusion criteria.